DK2440231T3 - Co-administration af et middel bundet til et tat-internaliseringspeptid med en mastcelledegranuleringshæmmer - Google Patents
Co-administration af et middel bundet til et tat-internaliseringspeptid med en mastcelledegranuleringshæmmer Download PDFInfo
- Publication number
- DK2440231T3 DK2440231T3 DK10786870.5T DK10786870T DK2440231T3 DK 2440231 T3 DK2440231 T3 DK 2440231T3 DK 10786870 T DK10786870 T DK 10786870T DK 2440231 T3 DK2440231 T3 DK 2440231T3
- Authority
- DK
- Denmark
- Prior art keywords
- degreanation
- inhibitor
- administration
- mast cell
- agent bonded
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title 1
- 238000011260 co-administration Methods 0.000 title 1
- 210000003630 histaminocyte Anatomy 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18594309P | 2009-06-10 | 2009-06-10 | |
| PCT/US2010/038226 WO2010144742A2 (en) | 2009-06-10 | 2010-06-10 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2440231T3 true DK2440231T3 (da) | 2020-01-13 |
Family
ID=43309471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10786870.5T DK2440231T3 (da) | 2009-06-10 | 2010-06-10 | Co-administration af et middel bundet til et tat-internaliseringspeptid med en mastcelledegranuleringshæmmer |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US8933013B2 (da) |
| EP (2) | EP3682895A1 (da) |
| JP (5) | JP5886192B2 (da) |
| AU (1) | AU2010259986B2 (da) |
| CA (2) | CA2765171C (da) |
| CY (1) | CY1122584T1 (da) |
| DK (1) | DK2440231T3 (da) |
| ES (1) | ES2765281T3 (da) |
| HR (1) | HRP20192230T1 (da) |
| HU (1) | HUE046640T2 (da) |
| LT (1) | LT2440231T (da) |
| PL (1) | PL2440231T3 (da) |
| PT (1) | PT2440231T (da) |
| SI (1) | SI2440231T1 (da) |
| WO (1) | WO2010144742A2 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| DK2320927T3 (da) * | 2008-07-09 | 2015-09-14 | Univ Copenhagen | Modificerede peptider som potente inhibitorer af PSD-95/NMDA-receptorinteraktionen |
| PL2440231T3 (pl) | 2009-06-10 | 2020-05-18 | Nono Inc. | Jednoczesne podawanie połączonego z peptydem internalizacyjnym tat środka oraz inhibitora degranulacji komórek tucznych |
| CN107090021A (zh) | 2009-09-22 | 2017-08-25 | 麦迪卡格公司 | 制备植物来源的蛋白质的方法 |
| TWI620816B (zh) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | 植物衍生蛋白回收方法 |
| CN103648518B (zh) | 2011-06-24 | 2016-11-16 | 诺诺公司 | 局部缺血的组合治疗 |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| AU2013352437B2 (en) * | 2012-11-28 | 2018-04-12 | Nono Inc. | Lyophilized formulation of TAT-NR2B9c |
| WO2016172219A1 (en) * | 2015-04-24 | 2016-10-27 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation |
| CN110809579B (zh) * | 2017-07-05 | 2023-04-04 | 拜西欧斯（北京）生物技术有限公司 | 多肽的药学可接受的盐及其应用 |
| MA50413A (fr) | 2017-10-19 | 2020-08-26 | Amgen Inc | Dérivés de benzimidazole et leurs utilisations |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
| US5331573A (en) | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
| JP2002531583A (ja) | 1998-12-11 | 2002-09-24 | バイオミラ，インコーポレイテッド | Ｍｕｃ−１アンタゴニストおよび免疫疾患の治療方法。 |
| US20040226056A1 (en) | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US20060148711A1 (en) | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| US7595297B2 (en) | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| DE60026313D1 (de) | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
| EP2269654A3 (en) | 1999-08-24 | 2011-04-13 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| US6864355B1 (en) | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20020032154A1 (en) | 2000-06-07 | 2002-03-14 | Peyman John A. | Interferon-suppressing placental lactogen peptides |
| WO2003024389A2 (en) | 2001-07-30 | 2003-03-27 | Immunex Corporation | T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using |
| EP1578365A4 (en) * | 2002-11-14 | 2009-09-23 | Arbor Vita Corp | MOLECULAR INTERACTIONS IN NEURONS |
| WO2004071531A1 (en) | 2003-02-13 | 2004-08-26 | Licentia Oy | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
| US20050209141A1 (en) * | 2003-10-17 | 2005-09-22 | Silver Randi B | Mast cell-derived renin |
| US20050256065A1 (en) * | 2004-01-26 | 2005-11-17 | Permasight | Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents |
| US7151084B2 (en) | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| ATE518535T1 (de) | 2005-12-30 | 2011-08-15 | Arbor Vita Corp | Kleinmolekulare hemmer von pdz-wechselwirkungen |
| EP2043671B1 (en) * | 2006-07-11 | 2020-05-20 | NoNO Inc. | Peptide and composition thereof for use in treating stroke with fever |
| EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| CN101678068B (zh) * | 2007-03-02 | 2015-05-13 | 诺诺公司 | 不抑制n型钙通道而治疗中风和其他疾病 |
| WO2009006611A1 (en) | 2007-07-03 | 2009-01-08 | Arbor Vita Corporation | Small molecule inhibitors of pdz interactions |
| BR122019000258B1 (pt) | 2007-07-26 | 2021-09-14 | Revance Therapeutics, Inc | Composição farmacêutica ou cosmética compreendendo um peptídeo catiônico e kit para administração da mesma |
| ES2328776B1 (es) | 2007-11-19 | 2010-07-06 | Proyecto De Biomedicina Cima S.L. | Peptidos con capacidad para unirse a escurfina y aplicaciones. |
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| DK2320927T3 (da) | 2008-07-09 | 2015-09-14 | Univ Copenhagen | Modificerede peptider som potente inhibitorer af PSD-95/NMDA-receptorinteraktionen |
| PL2440231T3 (pl) * | 2009-06-10 | 2020-05-18 | Nono Inc. | Jednoczesne podawanie połączonego z peptydem internalizacyjnym tat środka oraz inhibitora degranulacji komórek tucznych |
-
2010
- 2010-06-10 PL PL10786870T patent/PL2440231T3/pl unknown
- 2010-06-10 DK DK10786870.5T patent/DK2440231T3/da active
- 2010-06-10 ES ES10786870T patent/ES2765281T3/es active Active
- 2010-06-10 HU HUE10786870A patent/HUE046640T2/hu unknown
- 2010-06-10 PT PT107868705T patent/PT2440231T/pt unknown
- 2010-06-10 CA CA2765171A patent/CA2765171C/en active Active
- 2010-06-10 WO PCT/US2010/038226 patent/WO2010144742A2/en active Application Filing
- 2010-06-10 LT LTEP10786870.5T patent/LT2440231T/lt unknown
- 2010-06-10 CA CA3018494A patent/CA3018494C/en active Active
- 2010-06-10 JP JP2012515161A patent/JP5886192B2/ja active Active
- 2010-06-10 EP EP19210675.5A patent/EP3682895A1/en active Pending
- 2010-06-10 EP EP10786870.5A patent/EP2440231B1/en active Active
- 2010-06-10 AU AU2010259986A patent/AU2010259986B2/en active Active
- 2010-06-10 SI SI201031965T patent/SI2440231T1/sl unknown
- 2010-06-10 US US13/377,519 patent/US8933013B2/en active Active
-
2014
- 2014-12-29 US US14/585,028 patent/US9433685B2/en active Active
-
2015
- 2015-07-03 JP JP2015134712A patent/JP6238934B2/ja active Active
-
2016
- 2016-08-24 US US15/245,693 patent/US10046060B2/en active Active
-
2017
- 2017-09-19 JP JP2017179192A patent/JP6775478B2/ja active Active
-
2018
- 2018-07-12 US US16/034,235 patent/US20190038760A1/en not_active Abandoned
-
2019
- 2019-12-12 HR HRP20192230TT patent/HRP20192230T1/hr unknown
- 2019-12-23 CY CY20191101350T patent/CY1122584T1/el unknown
-
2020
- 2020-04-17 JP JP2020074428A patent/JP7209364B2/ja active Active
-
2022
- 2022-10-25 JP JP2022170797A patent/JP2023017813A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2440231T3 (da) | Co-administration af et middel bundet til et tat-internaliseringspeptid med en mastcelledegranuleringshæmmer | |
| SMT201600075B (it) | Composto di diamminocarbossammide eterociclica | |
| DK3101127T3 (da) | Alfa-amylasevarianter med forbedret stabilitet | |
| BRPI1009315A2 (pt) | agentes anti-inflamatórios | |
| BR112013012190A2 (pt) | composições adesivas e seus usos | |
| DK2498756T4 (da) | Tabletformuleringer af neratinibmaleat | |
| DK2603232T3 (da) | Stabile formuleringer af linaclotid | |
| DK2456853T3 (da) | Anvendelse af stamceller til reduktion af leukocyt-ekstravasation | |
| DK2272751T3 (da) | Ror til et skib | |
| BRPI1015091A2 (pt) | novo uso | |
| DK2506840T3 (da) | Anvendelser af hæmmere af hypoksi-fremkaldende faktorer | |
| DK2453858T3 (da) | Fremgangsmåde | |
| DK2215937T3 (da) | Rivejern med skrabeenhed | |
| DK2468677T3 (da) | Stablekran | |
| BR112013000369A2 (pt) | elemanto estrutural refratário | |
| DK2408289T3 (da) | Vendeplov med forbedret omsvingningsmekanisme | |
| DK2798065T3 (da) | Samtidig geninaktivering og undertrykkelse af geninaktivering i samme celle | |
| FR2955473B1 (fr) | Structure de presentoir | |
| DK2389184T3 (da) | Anti-dengue-aktivitet af cissampelos pareira-ekstrakter | |
| DK2459374T3 (da) | Laminatstrukturer | |
| DK2566505T3 (da) | Fremføring af kolesterylester til steroidogene væv | |
| FI20105348A0 (fi) | Proteolyyttisen entsyymin käyttö | |
| IT1399502B1 (it) | Formulazione di adesivi alcali-solubili con elevata resistenza all acqua | |
| ES1072567Y (es) | Estructura de fijacion de una carretilla | |
| BRPI1010136A2 (pt) | composto e usos de um composto |